E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic lymphocytic leukemia (CLL) is a malignant disease. CLL is the most common form of leukemia in western countries. Median age at diagnosis is 70 years, and only 10-15% of patients are younger than 50 years. Despite some therapeutic progress, standard treatment is not curative for CLL |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008976 |
E.1.2 | Term | Chronic lymphocytic leukemia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Determine whether nonmyeloablative conditioning and allogeneic HCT improves survival at 18 months for patients with fludarabine-refractory, FCR-failed, or del 17p CLL over that of historical controls (45% at 18 months) given CAMPATH-1H.[14] |
|
E.2.2 | Secondary objectives of the trial |
1. Estimate the overall response rate (CR + PR) by standard morphologic, flow cytometric, and molecular techniques. 2. Assess the rate of relapse/progression. 3. Define incidences of RRT and infections within the first 200 days and the incidence of TRM within the first year. 4. Estimate incidences of grade II-III and III-IV acute GVHD and chronic GVHD. 5. Assess the impacts of Rituximab 6. Graft-versus-leukemia analysis
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with a diagnosis of CLL (or small lymphocytic lymphoma) or Diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL. 2. Patients with B-Cell CLL or PLL who: a. Failed to meet NCI Working Group criteria2 (Appendix I) for complete or partial response after therapy with regimens containing fludarabine (or another nucleoside analog, e.g. 2-CDA, pentostatin) or with disease relapse within 12 months after completing therapy with fludarabine (or another nucleoside analog) containing regimen. b. Failed FCR or PCR combination chemotherapy at any time point. c. Patients with novo or acquired “17p deletion” cytogenetic abnormality. Patients should have received induction chemotherapy but could be transplanted in 1st CR. 3. Patients who have suitable HLA-matched related or unrelated donors willing to receive G-CSF, undergo leukopharesis to collect PBMC, and to donate stem cells
|
|
E.4 | Principal exclusion criteria |
1. Infection with HIV. 2. Active diagnosis of CNS involvement with CLL. For LP requirement, see Appendix O. 3. Patients unwilling to use contraceptive techniques before and for 12 months after HCT 4. Pregnant women or females who are breastfeeding. 5. The addition of cytotoxic agents for “cytoreduction” with the exception of tyrosine kinase inhibitors (such as imatinib mesylate), cytokine therapy, hydroxyurea, low dose cytarabine, chlorambucil, or rituxan will not be allowed within three weeks of the initiation of conditioning. 6. Active bacterial or fungal infections unresponsive to medical therapy. 7. Performance status: a. Karnofsky score < 60 (see Appendix B) for adult patients b. Lansky Play-Performance Score < 40 (Appendix C) for pediatric patients. 8. Severe organ dysfunction: a. Cardiovascular: i. Cardiac ejection fraction < 40%. Ejection fraction is required if age > 50 years or there is a history of prior transplant, anthracycline exposure or history of cardiac disease.
ii. Poorly controlled hypertension despite multiple antihypertensives.
b. Pulmonary: i. DLCO < 40%, TLC <40%, FEV1 <40% and/or requiring continuous supplementary oxygen, or severe deficits in pulmonary function testing as defined by pulmonary consultant service.
ii. The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules.
c. Hepatic: Patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension. Patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, hepatic damage with bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3 mg/dl, or symptomatic biliary disease.
9. Patients with active non-hematologic malignancies (except non-melanoma skin cancers).
10. Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than 5 years from the time of complete remission, and have a >20% risk of disease recurrence
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective of this protocol is to estimate survival using allogeneic HCT from related or unrelated donors after nonmyeloablative conditioning and peri-transplant Rituximab in patients with advanced CLL, and to gain a preliminary indication as to whether survival is improved compared to treatment with conventional salvage therapies. The primary endpoint will be survival at 18 months. The 18 months time point is chosen because prior experience with HCT indicates that survival reaches a relative plateau by that time, and thus offers an endpoint that can be evaluated somewhat more rapidly than 2 year survival. The estimated 18 months survival with standard treatment (Campath-1H) from historical patients is approximately 0.45. This treatment approach will be deemed promising for further study if we can achieve reasonable confidence that survival exceeds 0.45. Reasonable confidence will be taken to mean that the lower limit of a one-sided 80% confidence interval for the true survival fraction at 18 months is greater than 0.45. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Criteria for Termination of Study This will be a single stage trial of a single cohort of 40 patients. However, safety stopping rules will be imposed for acute grade IV GHVD, and transplant-related mortality at 200 days. These rules will be evaluated after every fifth patient is evaluable for the endpoint in question. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |